The Solidarity Trial is an international clinical trial launched by the World Health Organization (WHO) and its partners to help find an effective treatment for COVID-19. It is one of the largest international randomized trials of COVID-19 treatments, involving nearly 12,000 patients in 500 hospitals in more than 30 countries.
The Solidarity Experiment deals with evaluating the effect of drugs on 3 important outcomes for Covid-19 patients: mortality, the need for artificial respiration and the length of hospital stay.
The Solidarity Trial compares treatment options against a standard standard of care, to assess their relative efficacy in treating COVID-19. The Solidarity trial, involving patients in multiple countries, aims to assess whether any of the drugs improve survival, reduce the need for artificial respiration, or reduce hospital stay. Other drugs may be added to the trial based on the emerging evidence.
In general, until there is sufficient evidence, WHO warns against doctors and medical associations that recommend or give unproven treatments to patients with COVID-19, as well as to people who self-medicate with these drugs. WHO guidance on compassionate use can be found here.
Clinical trials are research studies that test how well new medical approaches work with people. Before an experimental treatment can be tested in humans in a clinical trial, it must have shown benefit in lab tests or animal research studies. The most promising treatments are then transferred to clinical trials, with the goal of identifying new ways to prevent, detect, diagnose or treat disease safely and effectively. Talk with your doctor about the ongoing progress of these trials, and to get the most up-to-date information about new treatments.
Building 1, floor 1, room (1/160)
Ext. No.: 21038 / 21054 / 52442